Receptor dynamics and kinetic discrimination contribute to selectivity of β1-adrenoceptor antagonists
Human β1-adrenoceptor (hβ1AR)-selective antagonists are widely used to suppress cardiac adrenergic signalling in cardiovascular disease with limited but still clinically relevant inhibition of hβ2AR functions in airway and vascular smooth muscle. However, achieving strong subtype selectivity remains challenging because...